Abstract:Amyloid fibril formation is a hallmark of several protein misfolding diseases, including systemic hereditary amyloidosis (SHA), in which lysozyme aggregates into plaques, causing inflammation in various tissues. SHA is a rare disease with no current drug treatment options. In our efforts to identify potential therapeutics for SHA, we investigated the inhibitory effects of benzamidine (BEN) on the fibrillation of human lysozyme (HL). Multiple biophysical assays demonstrated BENs ability to effectively prevent amyloid formation. Intrinsic fluorescence measurements highlighted BENs interaction with HL. We inferred the binding mode of BEN to HL through ITC experiments, molecular docking, and molecular dynamics simulations, confirmed BENs binding at the active site, particularly near stretch-2 (residues 52-64), a key region in its anti-amyloidogenic activity. This interaction differed from the previously reported interaction with HEWL. Further, microscopy analyses, including scanning electron microscopy (SEM) and transmission electron microscopy (TEM), further supported these findings by showing reduced fibril formation and alterations in fibril morphology in the presence of BEN. Importantly, BEN exhibited no cytotoxic effects in HEK-293 cells, reinforcing its potential as a therapeutic candidate for amyloidosis. These results provide strong evidence of BENs anti-amyloidogenic activity and offer a foundation for future drug development targeting lysozyme amyloidosis.

What problem does this paper attempt to address?

### Problems Addressed by the Paper This paper aims to address the issue of human lysozyme (HL) aggregation forming amyloid fibrils. Lysozyme amyloidosis is a rare hereditary disease characterized by abnormal aggregation of lysozyme in the body, leading to multi-organ dysfunction. Currently, there are no effective drug treatments for this disease, so finding potential therapeutic drugs that can inhibit lysozyme aggregation is of great significance. ### Research Background Lysozyme amyloidosis is a type of systemic hereditary amyloidosis (SHA), characterized by the formation of amyloid fibrils by lysozyme protein in the body, which deposits in various tissues and causes inflammatory responses. This disease mainly affects the liver, kidneys, and gastrointestinal tract, and patients may experience symptoms such as liver rupture, kidney failure, lymphadenopathy, Sjogren's syndrome, purpura, and gastrointestinal problems. Due to the lack of effective treatments, researchers are dedicated to finding compounds that can inhibit lysozyme aggregation. ### Research Objectives Researchers selected benzamidine (BEN) as a candidate drug and conducted a series of biophysical and molecular simulation experiments to explore the inhibitory effect of BEN on human lysozyme aggregation. Specifically, the main objectives of the study include: 1. **Verify the inhibitory effect of BEN on lysozyme aggregation**: Evaluate the inhibitory effect of BEN on lysozyme fibrillation through various biophysical methods (such as ThT fluorescence assay, Congo Red binding assay, ANS fluorescence assay, etc.). 2. **Determine the binding mode of BEN with lysozyme**: Study the binding site and interaction mechanism of BEN with lysozyme through isothermal titration calorimetry (ITC), molecular docking, and molecular dynamics simulations. 3. **Evaluate the cytotoxicity of BEN**: Detect the cytotoxicity of BEN in HEK-293 cells through MTT assay to ensure its safety as a potential therapeutic drug. ### Main Findings 1. **BEN effectively inhibits lysozyme fibrillation**: ThT fluorescence assay and Congo Red binding assay results show that BEN can significantly reduce the formation of lysozyme fibrils, and this inhibitory effect is dose-dependent. 2. **Binding site of BEN with lysozyme**: ITC experiments and molecular docking results indicate that BEN mainly binds at the active site of lysozyme, particularly near the stretch region 2 (residues 52-64), which plays a key role in anti-amyloidogenic activity. 3. **Cellular safety of BEN**: MTT assay shows that BEN has no significant cytotoxicity to HEK-293 cells at concentrations up to 800 μM, indicating its safety as a potential therapeutic drug. ### Conclusion This study provides comprehensive evidence that BEN can effectively inhibit the fibrillation process of lysozyme and exhibits good safety at the cellular level. These findings lay the foundation for the development of new therapeutic drugs for lysozyme amyloidosis. BEN or its analogs are promising potential candidates for the prevention and treatment of lysozyme amyloidosis.

Benzamidine-Mediated Inhibition of Human Lysozyme Aggregation: Differential Ligand Binding in Homologous Proteins

Basified Human Lysozyme: A Potent Inhibitor Against Amyloid Β-Protein Fibrillogenesis.

Inhibition behavior of Sennoside A and Sennoside C on amyloid fibrillation of human lysozyme and its possible mechanism

Biophysical insight into anti-amyloidogenic nature of novel ionic Co(II)(phen)(H2O)4]+[glycinate]- chemotherapeutic drug candidate against human lysozyme aggregation

Inhibitor discovery targeting the intermediate structure of β-amyloid peptide on the conformational transition pathway: Implications in the aggregation mechanism of β-amyloid peptide

Inhibitor discovery targeting the intermediate structure of beta-amyloid peptide on the conformational transition pathway: implications in the aggregation mechanism of beta-amyloid peptide.

N-Benzyl, N-phenethyl and N-benzyloxybenzamide derivatives inhibit amyloid-beta (Aβ42) aggregation and mitigate Aβ42-induced neurotoxicity

Insights into the interaction and inhibitory action of palmatine on lysozyme fibrillogenesis: Spectroscopic and computational studies

An in Vitro Elucidation of the Antiaggregatory Potential of Diosminover Thermally Induced Unfolding of Hen Egg White Lysozyme; A Preventive Quest for Lysozyme Amyloidosis.

Inhibition of Amyloid Β Aggregation and Cytotoxicity by Berbamine Hydrochloride.

Structural insights into the interactions of repositioning and known drugs for Alzheimer's disease with hen egg white lysozyme by MM-GBSA

Molecular insights into the phase transition of lysozyme into amyloid nanostructures: Implications of therapeutic strategies in diverse pathological conditions

Amyloid transformations of phenol soluble modulin α1 in Staphylococcus aureus and their modulation deploying a prenylated chalcone

Bifunctionality of Iminodiacetic Acid-Modified Lysozyme on Inhibiting Zn2+-Mediated Amyloid Β-Protein Aggregation.

Amyloid forming human lysozyme intermediates are stabilised by non-native amide-π interactions

Diphenylalanine as a Reductionist Model for the Mechanistic Characterization of β-Amyloid Modulators

Cooperative dissolution of peptidomimetic vesicles and amyloid beta fibrils

Discovery of small molecule benzothiazole and indole derivatives tackling tau 2N4R and a-synuclein fibrils

Protonation-State Dependent Modulation of Hen Egg-White Lysozyme Fibrillation under the Influence of a Short Synthetic Peptide

Atomistic Characterization of Binding Modes and Affinity of Peptide Inhibitors to Amyloid-Β Protein

Insight into the Inhibition Effect of Acidulated Serum Albumin on Amyloid Β-Protein Fibrillogenesis and Cytotoxicity.